Forbes
@forbes·2.1M subscribers·11.3K videos
How A Tool For Scientists Became A Billion-Dollar Opportunity | Forbes
Posted
June 22, 2020
Views
24,998
Likes
612
Comments
23
Engagement
2.54%
June 22, 2020
24,998
612
23
2.54%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
3:15Now PlayingSajith Wickramasekara was an undergrad at MIT when he came up with the idea for a cloud-based Crispr design tool to help scientists. Eight years later, Regeneron, Gilead and hundreds of other companies use its collaborative R&D software, and the company boasts a roaster of investors that includes Andreessen Horowitz, Benchmark, Menlo Ventures, Thrive Capital, and Y Combinator. As many customers rush to come up with vaccines and treatments for Covid-19, Benchling is on call as needed—but has stopped pushing software updates to those whose projects require total lockdown.
Read more about the Next Billion Dollar Startups on Forbes
Subscribe to FORBES
Stay Connected
Forbes newsletters
Forbes on Facebook
Forbes Video on Twitter
Forbes Video on Instagram
More From Forbes
Forbes covers the intersection of entrepreneurship, wealth, technology, business and lifestyle with a focus on people and success.
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
